Corpus lingüísticos del Instituto Caro y Cuervo (CLICC)

 Corpus Lingüísticos del Instituto Caro y Cuervo (CLICC) es una plataforma en línea para el almacenamiento, sistematización, administración y consulta de corpus, que nació con el objetivo de contar con un espacio para la salvaguarda de los archivos producto de las investigaciones del Instituto y que, actualmente, está disponible para que investigadores, comunidades o personas interesadas puedan publicar sus corpus sobre las lenguas de Colombia. CLICC es un espacio de acceso libre dirigido a público general y especializado interesado en explorar y contribuir a la documentación de la diversidad lingüística y cultural de Colombia. En este documento se describen sus características, funcionalidades, consultas y perspectivas futuras. También se explican los diversos ajustes que se han hecho para garantizar la publicación de corpus de distintos tipos, el respeto por los permisos y singularidad de cada corpus, y el aprovechamiento futuro de los archivos con fines diversos

Influence of Carbon Nanosheets on the Behavior of 1,2-Dipalmitoyl-sn-glycerol-3-phosphocholine Langmuir Monolayers

Carbon nanomaterials are widespread in the atmospheric aerosol as a result of the combustion processes and their extensive industrial use. This has raised many question about the potential toxicity associated with the inhalation of such nanoparticles, and its incorporation into the lung surfactant layer. In order to shed light on the main physical bases underlying the incorporation of carbon nanomaterials into lung surfactant layers, this work has studied the interaction at the water/vapor interface of carbon nanosheets (CN) with Langmuir monolayers of 1,2-Dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), with this lipid being the main component of lung surfactant layers and responsible of some of the most relevant features of such film. The incorporation of CN into DPPC Langmuir monolayers modifies the lateral organization of the DPPC at the interface, which is explained on the basis of two different effects: (i) particles occupy part of the interfacial area, and (ii) impoverishment of the lipid composition of the interface due to lipid adsorption onto the CN surface. This results in a worsening of the mechanical performance of the monolayers which may present a negative impact in the physiological performance of lung surfactant. It would be expected that the results obtained here can be useful as a step toward the understanding of the most fundamental physico-chemical bases associated with the effect of inhaled particles in the respiratory cycle

El valor de la recerca formativa per a la innovació docent i el desenvolupament competencial

2012PID-UB/117El projecte ha consistit en la introducció d’innovacions docents en dues assignatures del Grau de Pedagogia de la Facultat de Pedagogia ('Informàtica aplicada a la recerca educativa' i 'Orientació i Gènere') i una assignatura del Grau de Mestre en Educació Infantil de la Facultat de Formació del Professorat ('Observació i Innovació a l'aula) promovent la investigació formativa com a eina pedagògica. Conscients que la configuració de l'Espai Europeu d'Educació Superior planteja un gran repte per a l'aprofundiment de la investigació en el nou marc formatiu universitari, aquest projecte ha volgut validar mètodes d'ensenyament per al desenvolupament competencial (De Miguel, et al., 2006) que operativitzen la investigació formativa: l'Aprenentatge Basat en Problemes, l'Aprenentatge orientat a Projectes i l'ús de les narratives digitals (Rodríguez i Londoño, 2009) per fomentar l'autoaprenentatge i l'autogestió del coneixement. Els resultats obtinguts evidencien el valor d'aquestes estratègies pedagògiques instrumentalitzades per la investigació formativa per a l'assoliment de tres competències transversals comunes a la Universitat de Barcelona (Vicerrectorat de Política Docent, 2008): el compromís ètic, la capacitat d'aprenentatge i responsabilitat, i la capacitat comunicativa. A més també animen a avançar en el treball interdisciplinari per a l'avaluació de les mateixes, mitjançant l'elaboració de rúbriques específiques coherents amb les innovacions docents en les assignatures implicades.CONVOCATÒRIA D’AJUTS PER AL DESENVOLUPAMENT DE PROJECTES D’INNOVACIÓ DOCENT A LA UB. 2012PID-UB/11

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19

(1) Background: Different clinical presentations in COVID-19 are described to date, from mild to severe cases. This study aims to identify different clinical phenotypes in COVID-19 pneumonia using cluster analysis and to assess the prognostic impact among identified clusters in such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a large cohort of 12,066 COVID-19 patients, collected and followed-up from 1 March to 31 July 2020, from the nationwide Spanish Society of Internal Medicine (SEMI)-COVID-19 Registry. (3) Results: Of the total of 12,066 patients included in the study, most were males (7052, 58.5%) and Caucasian (10,635, 89.5%), with a mean age at diagnosis of 67 years (standard deviation (SD) 16). The main pre-admission comorbidities were arterial hypertension (6030, 50%), hyperlipidemia (4741, 39.4%) and diabetes mellitus (2309, 19.2%). The average number of days from COVID-19 symptom onset to hospital admission was 6.7 (SD 7). The triad of fever, cough, and dyspnea was present almost uniformly in all 4 clinical phenotypes identified by clustering. Cluster C1 (8737 patients, 72.4%) was the largest, and comprised patients with the triad alone. Cluster C2 (1196 patients, 9.9%) also presented with ageusia and anosmia; cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache, and sore throat; and cluster C4 (1253 patients, 10.4%) also manifested with diarrhea, vomiting, and abdominal pain. Compared to each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 18.6%; p 20 bpm, lower PaO2/FiO2 at admission, higher levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH), and the phenotypic cluster as independent factors for in-hospital death. (4) Conclusions: The present study identified 4 phenotypic clusters in patients with COVID-19 pneumonia, which predicted the in-hospital prognosis of clinical outcomes

Uncertainties and controversies in axillary management of patients with breast cancer

The aims of this Oncoplastic Breast Consortium and European Breast Cancer Research Association of Surgical Trialists initiative were to identify uncertainties and controversies in axillary management of early breast cancer and to recommend appropriate strategies to address them. By use of Delphi methods, 15 questions were prioritized by more than 250 breast surgeons, patient advocates and radiation oncologists from 60 countries. Subsequently, a global virtual consensus panel considered available data, ongoing studies and resource utilization. It agreed that research should no longer be prioritized for standardization of axillary imaging, de-escalation of axillary surgery in node-positive cancer and risk evaluation of modern surgery and radiotherapy. Instead, expert consensus recommendations for clinical practice should be based on current evidence and updated once results from ongoing studies become available. Research on de-escalation of radiotherapy and identification of the most relevant endpoints in axillary management should encompass a meta-analysis to identify knowledge gaps, followed by a Delphi process to prioritize and a consensus conference to refine recommendations for specific trial designs. Finally, treatment of residual nodal disease after surgery was recommended to be assessed in a prospective register

Habitat characterization and modeling of the potential distribution of the Military Macaw (Ara militaris) in Mexico

AbstractForest structure and composition have been used to assess the habitat characteristics that determine bird distributions. The patterns of distribution have been shaped by historical and ecological factors that play different roles at both temporal and spatial scales. The objectives of this research were to characterize the habitat of the endangered Military Macaw (Ara militaris) and evaluate the potential distribution of this species based on trends of land use changes in Mexico. We characterized the community structure and floristic composition of 8 forests that are currently used by the Military Macaw for breeding and feeding and compared the results with 6 similar forests characterized in other studies but without historical records of the presence of the Military Macaw. The Military Macaw preferred sites with high diversity of plant species dominated by trees from 4 to 15m in height and from 5 to 90cm in diameter at breast height. We identified 236 plant species in the 8 forests with 20 species (8.4%) used for nesting and feeding by the Military Macaw. The floristic composition is important for the presence of the Military Macaw because there were significant differences between forests with and without its presence. The potential area of distribution of the Military Macaw had decreased by 32% and the remnant areas are included in only 8 National Protected Areas. The protected areas of natural forests should be increased to preserve the sites of potential distribution and consequently the habitat of the Military Macaw in Mexico

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice